ArticleFrontiers in neurology2025
Comparative analysis of trends in the burden of motor neuron disease in China, the United States, and globally from 1990 to 2021: projections for 2022-2041.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Natural history of 441 cases of bulbar onset motor neuron disease (MND) in China: a single-center retrospective study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Motor Neuron Disease (MND) is a neurodegenerative disorder with low incidence (4-8 per 100,000), but high disability and mortality. This study analyzes MND burden in China, the U.S., and Globally from 1990 to 2021, covering trends in incidence, prevalence, mortality, Disability-Adjusted Life Years (DALYs), age-standardized incidence rate (ASIR), age-standardized prevalence rate (ASPR), age-standardized mortality rate (ASMR), and age-standardized DALYs rate (ASDR), and predicts changes for 2022-2041. Methods: Using Global Burden of Disease (GBD) data, Joinpoint regression analysis identified key turning points, and decomposition analysis quantified the contributions of aging, population growth, and epidemiological factors. The Autoregressive Integrated Moving Average (ARIMA) model forecasted future trends. Results: From 1990 to 2021, the incidence, prevalence, mortality, and DALYs of MND in China, the United States, and globally showed significant increases, with the largest increase observed in mortality (China +126%, USA +118%, global +156%). The annual average percentage changes (AAPC) were as follows: ASIR (-1.10, 0.45, -0.15%), ASPR (0.26, 0.39, -0.04%), ASMR (0.57, 0.51, 0.58%), and ASDR (-0.15, 0.14, 0.25%). Joinpoint regression analysis showed that China's ASIR declined from 1990 to 2015 and began to rise in 2015, with ASPR continuing to increase and ASMR and ASDR fluctuating. In the US, ASIR continued to rise, ASPR decreased before 1995 and then increased, with fluctuations in ASMR and ASDR. Globally, ASIR and ASPR decreased from 1990 to 1995, increased from 1995 to 2005, and then declined from 2005 onwards, with ASMR continuing to increase. Decomposition analysis indicated that aging populations aged 65 and above were the primary driving factor. Gender and age analysis revealed that males under 69 bear a higher MND burden. Predictions for 2022-2041 show that in China, male ASIR will decline, while female ASIR will rise, with ASPR, ASMR, and ASDR remaining stable; in the US, male ASIR will rise, ASPR will first increase and then decrease, with ASMR and ASDR remaining stable; globally, ASIR, ASPR, and ASMR will remain stable, while male ASDR will rise and female ASDR will remain stable. Conclusion: The burden of MND continues to increase in China, the United States, and globally, with elderly males particularly affected, while low- and middle-income countries face more severe challenges. This study provides crucial data for developing global public health strategies and medical policies, aiming to effectively reduce the burden of MND through targeted interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.